TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Use of Oral Prednisone for Acute Asthma Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Asthma Control Days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety of IV administration of [F-18]T808
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Antibody (AB) Formation
Endpoint domain: Adverse events/effects
Primary endpoint: Internal validity of the visual acuity questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression Change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time on Intensive Care Unit (ICU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height difference at one year of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Central Line Associated Bloodstream Infections (CLABSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of beta-lactams concentrations above plasma therapeutic levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Perceived Stress Scale (PSS-10)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Posttraumatic Checklist-Civilian (PCL-C)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: pharmacokinetics of paliperidone ER
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of tender and swollen joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Disease activity score DAS 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound score US-7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in leg muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in cardiac autonomic neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in protective stepping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of children diagnosed with dissociative disorders
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Clinically Significant Changes in Safety Laboratory Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Changes in Physical Examination Findings, Vital Signs, or Electrocardiogram Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma-related exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Knowledge Retention of Genetic Counseling Information
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Satisfaction With Genetic Counseling Session
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self reported KOA pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: occurrence of postoperative delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With Diphtheria and Tetanus Seroprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Diphtheria and Tetanus Booster Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentrations (GMC) of Anti Pertussis Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects With Pertussis Antigen Booster Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stone volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with AHI reduced by at least 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of positive microbiological culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Detection of adenovirus in conjunctival specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in number of urinary incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Root Coverage Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Continuous smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Units on a Scale (0-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Power, strength and speed improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in retinal nerve fiber thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length of time for anesthetic block to reach T4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Hematological Toxicities of the Indicated Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Developed an Anti-raxibacumab Antibody Response
Endpoint domain: Adverse events/effects
Primary endpoint: Abnormal imaging results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject assessment of pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Titration Pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Very-Low-Density-Lipoprotein-Triglyceride (VLDL-TG) secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insomnia Severity Index (ISI) Change From Baseline at 8 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Insomnia Severity Index (ISI) Change From Baseline at 20 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Volume of urinary leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Mean Percentage of Headache Days
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Plasma lipid metabolomic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: symptomatic SVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 28-day ICU mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Late adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Magnitude of Hyperthermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Hyperthermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of corneal melting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KPro retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants Who Experienced at Least One Intraocular Pressure (IOP) Measurement ≥30 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change From Baseline in Corneal Endothelial Cell Density (ECD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maternal antiretroviral drug resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HCV Antibody Completion within 4 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of technology
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pathogenic germline mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevention of chemotherapy-induced leukocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Occurrence rate of pancreatitis and cholecystitis
Endpoint domain: Mortality/survival
Primary endpoint: Severity of pancreatitis and cholecystitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inform gain analysis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction analysis
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Diagnostic accuracy of the screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of BIBF 1120
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Accuracies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular pressure measurements agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Central corneal thickness measurements agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: 28-day Ventilator-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 28-day ICU-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scapulo-humeral rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure Rate Against T. Trichiura and Hookworm Infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: functional beta cell mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AST and ALT Liver enzyme levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erectile Function Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Erections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 meter Sprint Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Broad Jump Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Push-up Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hexagon Agility Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plank Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 meters On-ice Sprint Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cornering S Turn Agility Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Power Wheelchair Driving Skill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-rank Improvement on a 7-point Ordinal Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence and nature of adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: absence of severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Morbidity or mortality
Endpoint domain: Mortality/survival
Primary endpoint: Quantitative myometry (QMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Indol profile in platelet rich plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of IPV (perpetration and victimisation)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of severe physical and sexual IPV
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with adverse events after transplantation
Endpoint domain: Adverse events/effects
Primary endpoint: Detection frequency of CMV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety of Scopolamine HBr
Endpoint domain: Adverse events/effects
Primary endpoint: Vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of neurocognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: length of stay in ED
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Physiologic and Metabolic activity (VO2, VCO2, HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline Functional Status Score (FSS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction of local-regional failure rate
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Concentration-Time Curve (AUC0-336)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ Over the Entire Course of Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Concentration-time Curve (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve a 25% reduction in Body Mass Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Number of Days Without Bleeding or Spotting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle function of the deep cervical flexors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Micafungin concentration in plasma (AUC0-48)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dermatologic Assessment at the Patch Application Site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Generalized Anxiety Disorder Status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Negative Predictive Value at 70 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative Predictive Value at 105 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: culture-positive rate of epidural needles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Fugl-Meyer Motor Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of local vancomycin powder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Glycosylated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tolerability to sputum induction test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the Shang Ring technique
Endpoint domain: Adverse events/effects
Primary endpoint: Active extension of the PIP joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Postoperative changes in lung volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postoperative changes in airway resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diaphragm ultrasound function evaluation (excursion and thickening)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: All-cause re-admissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sound speed resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: attenuation resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fold Change in Long Chain Fatty Acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Fine Wrinkling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Premature Infant Comfort Scale (PICS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: time to restore normal activities after surgery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Surgical Wound Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients who are relapse-free
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients who are not a treatment failure
Endpoint domain: Mortality/survival
Primary endpoint: Urinary ethyl glucuronide (EtG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's pain perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: coronary artery disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Positive Agreement of CADence Device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VAT mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Achieving ACR 20% Improvement Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eyelash growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of 10 mg Prana 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of 20 mg Prana 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unique inflammatory VOC profiles in exhaled air
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hours sedentary
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SICI Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of items recalled
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attitudes towards plant sterol claims
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Understanding of plant sterol claims
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Testosterone Serum Levels Below 0.5 ng/mL for at Least 28 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Quality of life evaluative index: patients report outcomes for SAP
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life evaluative index: self-administrated scale of SAP
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in weight pre- to post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in caloric intake pre- to post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pathologic tumor regression grade (TRG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CSF cell count changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence or absence of bronchiolitis obliterans syndrome (BOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forgotten Joint Score (FJS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percent change in cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ability to correctly assemble and use the X-PLO2R POC
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: BCI Performance Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinematic Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained virologic response (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-establishment of the Gag Reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety measure
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants in Remission at Week 62
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of primary fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue